Novel Immunotherapies, Cell Therapies and Cancer Vaccines
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".
Deadline for manuscript submissions: 30 April 2025 | Viewed by 37
Special Issue Editor
2. Department of Medicine, University of Oklahoma Health Sciences Center, Andrews Academic Tower, 800 Stanton L. Young Blvd, Oklahoma City, OK 73104, USA
Interests: immunotherapy; CAR-T cells; tumor microenvironment; checkpoint protein; hypoxia; tumor survival signaling
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Novel cell therapies, immunotherapies, antibodies, bispecific antibodies and vaccines demonstrate remarkable results in the treatment of patients with cancer. Several CAR-T cell therapies and CAR-NK cells are used in clinics. The method encompassing T cell engagers attracting T cells to the tumor side is another example of a promising therapy for targeting solid tumors. Vaccines are also an exciting area of immunotherapy against cancer.
This issue will focus on different immunotherapies, autologous and allogeneic cell therapies, antibodies and vaccines. We welcome reports focusing on the tumor microenvironment, checkpoint proteins, hypoxia, tumor-associated macrophages, cancer-associated fibroblasts, vascular, angiogenic pathways, cytokines, chemokines, T reg cells blocking immune response and tumor intracellular pathways. Moreover, this issue will highlight the next-generation, personalized immunotherapy approaches and vaccines that will be developed in the future to enhance how we treat patients.
Dr. Vita Golubovskaya
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cell therapy
- vaccine
- cancer
- immunotherapy
- antibody
